Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B. - Wikidata - awgldk - TriplyDB

Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B.

Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B.

http://www.wikidata.org/entity/Q46434842

about

11 C-PIB-PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI)Shift in brain metabolism in late onset Alzheimer's disease: implications for biomarkers and therapeutic interventions Amyloid PET in clinical practice: Its place in the multidimensional space of Alzheimer's disease PET amyloid-beta imaging in preclinical Alzheimer's disease Early AD pathology in a [C-11]PiB-negative case: a PiB-amyloid imaging, biochemical, and immunohistochemical study.Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease DTI-MRI biomarkers in the search for normal pressure hydrocephalus aetiology: a review.Deficient high-affinity binding of Pittsburgh compound B in a case of Alzheimer's disease APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging.In vivo human amyloid imaging.Increased metabolic vulnerability in early-onset Alzheimer's disease is not related to amyloid burden Reduced CSF turnover and decreased ventricular Aβ42 levels are related Mapping brain beta-amyloid.PIB binding in aged primate brain: enrichment of high-affinity sites in humans with Alzheimer's disease.Cognition, glucose metabolism and amyloid burden in Alzheimer's disease.Multimodal predictors for Alzheimer disease in nonfluent primary progressive aphasia.Correlation of brain amyloid with "aerobic glycolysis": A question of assumptions?Biomarkers of Alzheimer's disease risk in peripheral tissues; focus on buccal cells.Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease Transforming cerebrospinal fluid Aβ42 measures into calculated Pittsburgh Compound B units of brain Aβ amyloid Is there a neuropathology difference between mild cognitive impairment and dementia?Brain ventricular volume and cerebrospinal fluid biomarkers of Alzheimer's disease In vivo fibrillar beta-amyloid detected using [11C]PiB positron emission tomography and neuropathologic assessment in older adults.Prediction of cognitive decline based on hemispheric cortical surface maps of FDDNP PET Amyloid-β associated cortical thinning in clinically normal elderly.Biomarkers in Alzheimer's disease.Cerebrospinal fluid biomarker and brain biopsy findings in idiopathic normal pressure hydrocephalus.A survey of FDG- and amyloid-PET imaging in dementia and GRADE analysis Frequency of Alzheimer's disease pathology at autopsy in patients with clinical normal pressure hydrocephalus.Imaging brain effects of APOE4 in cognitively normal individuals across the lifespan.Human apoE isoforms differentially regulate brain amyloid-β peptide clearance PET amyloid imaging as a tool for early diagnosis and identifying patients at risk for progression to Alzheimer's disease Not quite PIB-positive, not quite PIB-negative: slight PIB elevations in elderly normal control subjects are biologically relevant Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia.Correlation of amyloid PET ligand florbetapir F 18 binding with Aβ aggregation and neuritic plaque deposition in postmortem brain tissue.Amyloid imaging in Alzheimer's disease: comparison of florbetapir and Pittsburgh compound-B positron emission tomography Amyloid imaging in the differential diagnosis of dementia: review and potential clinical applications.Molecular imaging in Alzheimer's disease: new perspectives on biomarkers for early diagnosis and drug development.Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology.

P2860

Q24194742-5AFA6E95-6126-4E4A-B8B5-7354DFAA1E69 Q26830740-8AF38A50-94D7-47D8-9C42-71AE8AC00325 Q27009411-91DB6E7C-E50D-4154-859E-E355916DBDCD Q30040695-21AAB5AD-220C-4142-B104-C03E7075B942 Q30422060-8582C1C5-17BA-4DB1-B627-45C87FEACE03 Q30497749-180B8BFB-5334-4FB8-BB6B-92BA6E601FA1 Q30863998-678B6FD8-BF4D-45E9-8DB5-FA093082F32D Q33494855-783E2DE2-EC15-40CF-89A0-712B6FF9E26C Q33695738-8C997141-B41E-4921-B963-C13272D9742C Q33790277-A4945500-1C02-4452-930F-81EFABA2C1F8 Q33803956-0823AD54-B436-4386-A7B0-037C389918ED Q33898968-266174DB-2054-48C6-9A37-957937B92DEB Q33899600-128025F6-21FC-497C-9C65-B11E6B76ED0C Q33936595-49E68A9A-E59F-4C70-AFD5-DB2936ED85F8 Q34061233-A2FC4080-2A3A-48DC-AC74-74BA51E55A39 Q34099180-2FFBB0EE-4301-4D7C-93A9-39778D25147C Q34200085-C09FD4FA-C1E3-4FCA-8E09-0745CF842847 Q34201730-80DD823C-D0F7-4A47-A733-64E483C8B195 Q34247849-72610DD5-D14D-4CB5-B0F2-EE92D17F960A Q34699437-45ABC61B-8072-4AEB-8B23-06C236E7710C Q34776816-7EA2B03F-8B04-47D7-900A-35121DBC8502 Q34802970-F6486632-A0B0-4D90-8A11-2ADA7890772C Q34865982-D8D69C1E-1254-42ED-9CBC-464B3A0881A3 Q35015645-DE2DD7E7-6276-4D39-A4A2-90609C876967 Q35053524-540CAD5F-9C9F-4E74-8104-4E6BBCC4B8C7 Q35113795-5027EA6F-D8D6-4AC2-A5E0-2D3BC133ED3A Q35123209-46794F89-BA66-46D8-9FF1-43DBCFC39C7B Q35158547-2ABF21DA-B60C-46B2-B6DE-322B3D734DF9 Q35196359-370E5178-90B6-42DF-BA35-63A710E0C641 Q35229601-E372004A-67B4-4717-8EA1-F2349076F20A Q35334161-7EA4F790-ABAC-4D15-9666-6036E955A864 Q35579225-63FD7541-73BD-455C-A60E-C848DE230287 Q35592672-EE91AB76-38B7-4963-B78F-BD1F884E7EDA Q35600979-7CFE6022-6336-4A17-9BA8-932258C8B0A1 Q35776066-FE159DA8-1521-469E-90C2-12A61D8F9840 Q35777166-44AA613F-B556-40AA-A8E6-A46558A796B9 Q35840614-89FB60E8-DBDB-4959-8153-35F51A286756 Q35840623-42C43130-F72E-4B44-9585-1531324258E6 Q35896890-FF0DFAF2-9A80-460B-B5A7-1942096FE30F Q35940191-41438418-F62C-480D-A1F4-A8E264B5BB1D

P2860

Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B.

http://www.wikidata.org/entity/Q46434842

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh-hant

name

Assessment of beta-amyloid in ...... labeled Pittsburgh Compound B.

@en

Assessment of beta-amyloid in ...... labeled Pittsburgh Compound B.

@nl

type

label

Assessment of beta-amyloid in ...... labeled Pittsburgh Compound B.

@en

Assessment of beta-amyloid in ...... labeled Pittsburgh Compound B.

@nl

prefLabel

Assessment of beta-amyloid in ...... labeled Pittsburgh Compound B.

@en

Assessment of beta-amyloid in ...... labeled Pittsburgh Compound B.

@nl

P1433

Q46434842-362A732B-A4A1-4D1E-B57A-06DA831EE45D

P1476

Q46434842-244C88CA-4F3F-43D5-9FB8-7569267AD61E

P2093

Q46434842-14637256-4287-4803-BC74-CE68A83C1B27

Q46434842-2AF8B8C2-8F4A-485F-9651-4B5E49A40C6F

Q46434842-49F1B1C8-7B71-44B6-ACF1-D5F60B99564A

Q46434842-6F1BE79A-EB0E-41D8-8B80-3C7B33A98FCB

Q46434842-83D6454F-D4EC-4523-866E-42E522D03D9C

Q46434842-897992CC-6EAB-4C61-86BC-4C9F2E831FF3

Q46434842-97843CA2-C750-4CFE-AE92-F459846129E7

Q46434842-A13AB111-7ECA-4108-A0D4-A6699D2B73A9

Q46434842-AEB9810B-F7F5-42D7-A0D0-FAF7EAAAA800

Q46434842-F3E20F64-3FEF-495C-AA03-B85EA9F0CB60

P304

Q46434842-D1281EFF-DA15-4196-BA17-096E2F3E3236

P31

Q46434842-E7D0CBC0-87B1-47D6-9170-3C57604D89F6

P356

Q46434842-63A89629-50AC-43CC-9B68-DCC3C9F565A9

P433

Q46434842-80357511-BE60-498A-BFE0-779FAF341D61

P478

Q46434842-DAAF3B41-5F31-4B6A-BDA1-AC3813B62D67

P50

Q46434842-7EF0D113-9D0D-40C2-979C-4F7D7578C2B8

P577

Q46434842-5B0F63DA-A5C1-4E49-B5B4-B70A56B9046C

P5875

Q46434842-DA49DE4E-1849-4054-8E6F-41125D371BD6

P698

Q46434842-016A565A-9161-4072-8DF6-92D869471A6B

P356

ARCHNEUR.65.10.NOC80013

P1433

P1476

Assessment of beta-amyloid in ...... labeled Pittsburgh Compound B.

@en

P2093

Irina Alafuzoff

http://www.w3.org/2001/XMLSchema#string

Jaakko Rinne

http://www.w3.org/2001/XMLSchema#string

Juha E Jääskeläinen

http://www.w3.org/2001/XMLSchema#string

Juha O Rinne

http://www.w3.org/2001/XMLSchema#string

Kjell Någren

http://www.w3.org/2001/XMLSchema#string

Sakari Savolainen

http://www.w3.org/2001/XMLSchema#string

Sargo Aalto

http://www.w3.org/2001/XMLSchema#string

Tero Tapiola

http://www.w3.org/2001/XMLSchema#string

Timo Suotunen

http://www.w3.org/2001/XMLSchema#string

Tuula Pirttilä

http://www.w3.org/2001/XMLSchema#string

P304

1304-1309

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/ARCHNEUR.65.10.NOC80013

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

65

http://www.w3.org/2001/XMLSchema#string

P50

Hilkka Soininen

P577

2008-08-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23163679

http://www.w3.org/2001/XMLSchema#string

P698

18695050

http://www.w3.org/2001/XMLSchema#string